Trial Profile

Clinical Study on the Safety and Efficacy of PRG-1801 for the Treatment of Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRG 1801 (Primary)
Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
Focus Adverse reactions

Most Recent Events

28 Nov 2025 Planned number of patients changed from 9 to 6.
28 Nov 2025 Planned primary completion date changed from 15 Aug 2025 to 15 Dec 2026.
04 Dec 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com